טוען...
MiR-34a Chemo-Sensitizes Bladder Cancer Cells To Cisplatin Treatment Regardless Of P53-Rb Pathway Status
MiR-34a is a downstream effector of p53 that has been shown to target several molecules associated with cell cycle and cell survival pathways. As alterations in these pathways are frequent in muscle invasive transitional cell carcinoma of the bladder (MI-TCC), for example mutation or loss of p53 and...
שמור ב:
| הוצא לאור ב: | Int J Cancer |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4568996/ https://ncbi.nlm.nih.gov/pubmed/21702042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.26256 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|